Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 215Uterine Cervical Neoplasms 144Endometrial Neoplasms 111Fallopian Tube Neoplasms 78Breast Neoplasms 59Carcinoma, Non-Small-Cell Lung 43Colorectal Neoplasms 40Stomach Neoplasms 35Melanoma 31Carcinoma, Renal Cell 29Prostatic Neoplasms 28Neoplasms 28Carcinoma, Ovarian Epithelial 28Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Esophageal Neoplasms 25Neoplasm Metastasis 24Lung Neoplasms 23Urinary Bladder Neoplasms 22Head and Neck Neoplasms 21Colonic Neoplasms 20Vulvar Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 14Uterine Neoplasms 13Small Cell Lung Carcinoma 13Sarcoma 13Rectal Neoplasms 12Peritoneal Neoplasms 12

Interventions

pembrolizumab 1E7046 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Spinocerebellar Degenerations × Gynecologic × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡